Navigation Links
Vystar Corporation and Revertex Malaysia Sign Vytex(TM) NRL Production Contract

ATLANTA, April 23 /PRNewswire/ -- Vystar Corporation announced today that Revertex Malaysia, the world's largest producer of prevulcanized rubber lattices and post vulcanizable latex compounds, has contracted to produce Vytex(TM) natural rubber latex (NRL).

"This contract represents tremendous capacity to produce Vytex NRL and meet the growing demands of manufacturers who are currently evaluating this revolutionary product," said Vystar CEO William R. Doyle. According to Doyle, the Revertex contract accounts for tens of thousands of metric tons in Vytex NRL production. Revertex is known for its expertise in producing some of the most stable latex compounds. In addition, it supplies many of the types of manufacturers that are waiting to introduce Vytex NRL into their product lines. As part of the contract, Vystar now has the cooperation of the Revertex staff, from sales to technical support, worldwide.

Vystar's proprietary Vytex NRL process chemically modifies NRL to reduce the allergenic proteins commonly found in it. The resulting Vytex NRL represents a dramatic breakthrough in the global search for a natural rubber latex in which the antigenic proteins that trigger allergic reactions are deactivated without reducing elasticity. Published data indicate that up to 6 percent of the general public and 18 percent of health care workers have some level of latex allergy. Ongoing test results consistently show that the Vytex technology reduces antigenic proteins to levels considered undetectable by the most widely used standard tests.

"Revertex evaluation and production runs of Vytex NRL over the past year have proven both the repeatability of the production of low-protein NRL and the economic feasibility of its production. The physical and chemical properties as well as the protein levels and storage stability were outstanding," Doyle said. The cost of Vytex is significantly less than the synthetic alternatives in targeted markets of manufactured products.

He went on to point out that manufacturers in the medical, industrial, consumer and foam industries have signed agreements to begin evaluation trials on Vytex NRL, and the product is already in the hands of many manufacturers. Vystar began shipping Vytex NRL in late February to leading surgical and exam glove, condom, sponge, medical device and foam manufacturers in the Americas, Europe and Asia.

Doyle said he feels there is every reason to believe that manufacturers will have products made with Vytex NRL in production before the end of this year. "We are very optimistic based both on the reception Vytex NRL has received from the manufacturing community and the consistent testing results we have had from the Vytex NRL production runs with Revertex Malaysia," Doyle said.

Previously, Revertex and Vystar had been working together under a letter of intent. The contract makes Revertex the first contracted producer of Vytex NRL.

Vytex NRL has been in development since 2002. The current manufacturer evaluation trials enable manufacturers to work with Vytex NRL within their own production environment to assess performance in their products and applications. Earlier trials at select condom, glove and other medical device manufacturers demonstrated that Vytex NRL integrates seamlessly into most manufacturing processes in place of either NRL or synthetic substitutes with few to no changes to the overall process.

The development of Vytex NRL is a potential advantage for manufacturers as diverse as the makers of balloons, surgical and examination gloves, medical devices, foam mattresses, adhesives, infant supplies and threads. It is particularly critical to the health care industry where such a high percentage of workers are affected by some level of latex allergy believed to be caused by repeated exposure to latex with high levels of antigenic proteins.

About Vystar Corporation: Vystar Corporation, incorporated in 2003, is a privately funded corporation located in the Atlanta area. It is included in the portfolio of Universal Capital Management, Inc. (OTC BB:UCMT.OB), a business development company that provides management and strategic growth resources to emerging growth companies. The company's operations have been focused substantially on early-stage research, development, testing and commercialization of the Vytex NRL process. Vystar, named a 2007 Top 10 Innovative Technology Company in Georgia by the Technology Association of Georgia (TAG), holds two U.S. patents for the Vytex(TM) NRL technology, with additional filings pending. For more information, please visit

About Revertex Malaysia: Revertex Malaysia is a division of Yule Catto, one of the United Kingdom's most successful specialty chemicals companies with interests worldwide. Revertex Malaysia is the world's largest producer of prevulcanized rubber lattices and post vulcanizable latex compounds. It is also the sole producer of evaporated rubber lattices with three manufacturing operation sites in Malaysia and Thailand. Revertex natural rubber latex compounds flow into various industries, such as gloves, catheters, condoms, carpets, shoes, balloons, child care products, toys, masks, artificial flowers, road construction, water proofing and many more.

Forward-looking Statements:

Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words, such as Vystar Corporation "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe Vystar's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Vystar as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Vystar believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Vystar does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

SOURCE Vystar Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: